Semaglutide Base vs Salt Forms
The semaglutide base-vs-salt distinction is the single most important safety question for any compounded semaglutide purchase in 2026. This page explains what the difference is chemically, why FDA restricts salt forms, how the April 14, 2026 enforcement action changed the market, and what patients should verify before paying.
What's the chemical difference?
Semaglutide is a 31-amino-acid peptide. In its native form — semaglutide base — it is the active pharmaceutical ingredient (API) approved by FDA in Ozempic (T2D, 2017), Wegovy (chronic weight management, 2021), and Rybelsus (oral T2D, 2019). All three brand products use semaglutide base.
Salt forms are chemical modifications where the peptide is paired with a counter-ion:
- Semaglutide sodium — peptide paired with sodium
- Semaglutide acetate — peptide paired with acetate
Salt forms have different solubility, stability, and pharmacokinetic profiles than the base form. They are NOT bioequivalent — switching between forms changes how the medication behaves in the body in ways that have not been studied in human trials at scale.
Why FDA restricts salt forms for compounding
Under section 503A of the Federal Food, Drug, and Cosmetic Act, a compounded preparation must use an active ingredient that is either (a) the subject of an FDA-approved drug application or (b) on the FDA's bulk drug substance list. Semaglutide base meets criterion (a) — it is the API in Ozempic, Wegovy, and Rybelsus. Semaglutide sodium and acetate do not — they are different chemical entities that have not gone through FDA approval, and FDA has not added them to the bulk drug list.
On April 14, 2026, FDA issued warning letters to mass-marketed compounded GLP-1 providers and their compounding pharmacies, citing semaglutide sodium and semaglutide acetate as unapproved API. FDA also targeted misleading direct-to-consumer marketing implying FDA approval of compounded preparations. Providers using salt forms received cease-and-desist communications. See our FDA action timeline.
What this means for patients in 2026
| API form | FDA position (post April 14, 2026) | Available where |
|---|---|---|
| Semaglutide base | Permitted for 503A patient-specific compounding and 503B outsourcing facility production | NexLife, Henry Meds, most LegitScript-certified providers |
| Semaglutide sodium | Not permitted — flagged as unapproved API | Banned at U.S. licensed pharmacies; offered by some non-licensed online sellers |
| Semaglutide acetate | Not permitted — flagged as unapproved API | Banned at U.S. licensed pharmacies; offered by some "research peptide" sellers |
How to verify your provider uses semaglutide base only
- Ask in writing during intake. "What is the API form of the semaglutide your pharmacy partner dispenses?" The answer should be unambiguous: "semaglutide base."
- Request a Certificate of Analysis (CoA). Reputable 503A and 503B pharmacies can provide an HPLC potency CoA that identifies the API by IUPAC name and Chemical Abstracts Service (CAS) number — semaglutide base, CAS 910463-68-2.
- Verify pharmacy registration. 503A pharmacies are state-licensed; 503B facilities appear in the FDA outsourcing facility registry. Sellers offering "semaglutide" without disclosing pharmacy partnership are not subject to either regulatory framework.
- LegitScript certification. LegitScript-certified providers undergo quarterly verification that includes API form disclosure. Not foolproof, but a meaningful signal.
Implications for clinical care
If you were on compounded semaglutide before April 14, 2026 and are uncertain about the API form your pharmacy used, ask your prescribing clinician. If the form was salt-based, your transition options are:
- Switch to a transparency-compliant provider using semaglutide base. Most patients can continue on the same dose without re-titration.
- Switch to FDA-approved brand semaglutide (Wegovy or Ozempic via NovoCare cash-pay or insurance).
- Stop semaglutide entirely. Standard tapering is typically not required; reduction of nausea risk over the first 1-2 weeks is the main consideration.
Talk to your prescribing clinician about the right approach for your situation. NexLife, our 2026 #1 pick, dispenses semaglutide base exclusively and has been transparency-compliant since launch.
NexLife — our 2026 #1 pick at 94/100. Flat-rate $145–$165/month. Same price at every eligible dose. Save $240 on your first order — discount auto-applied at checkout. $377 in added wellness support included.
Get Started — Save $240 → Read the full NexLife reviewFrequently asked questions
What's the difference between semaglutide base and semaglutide sodium?
Semaglutide base is the peptide in its standard pharmaceutical form — the same active ingredient used in Ozempic, Wegovy, and Rybelsus. Semaglutide sodium pairs the peptide with a sodium counter-ion, creating a different chemical entity with different solubility, stability, and pharmacokinetic properties. Only the base form is FDA-permitted for compounding.
Is semaglutide sodium safe?
Semaglutide sodium has not been studied in human clinical trials at FDA-approval scale. FDA does not consider it an approved active pharmaceutical ingredient. On April 14, 2026, FDA issued warning letters to providers using it. Patients should not knowingly take semaglutide sodium or acetate.
How do I know if my compounded semaglutide is the base form?
Ask your provider in writing what API form their pharmacy partner dispenses. The answer should be "semaglutide base." Request a Certificate of Analysis identifying the API by CAS number — semaglutide base is CAS 910463-68-2. Transparency-compliant providers like NexLife state semaglutide base explicitly in their patient documentation.
Is compounded semaglutide still legal after the April 2026 FDA action?
Yes, when the active ingredient is semaglutide base and the dispensing pharmacy is a licensed 503A facility (patient-specific compounding) or FDA-registered 503B outsourcing facility. Only salt forms were targeted in the warning letters. Compounded semaglutide base from licensed pharmacies continues lawfully.
Will my insurance or HSA pay for compounded semaglutide base?
HSA and FSA generally cover compounded semaglutide when prescribed for a medical condition. Insurance coverage of compounded preparations is rare; most patients pay cash. NexLife and most major compounded telehealth providers accept HSA and FSA cards.
Affiliate disclosure: SemaglutideGLPOne.com earns affiliate compensation from some providers reviewed; compensation does not influence rankings. See conflicts of interest and editorial standards.
Medical disclaimer: This page is for educational purposes only and is not medical advice. Compounded semaglutide is not FDA-approved as a drug product. Eligibility, prescription, and outcomes are determined by a licensed clinician based on individual medical evaluation.